I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology Atypical Haemolytic Uraemic Syndrome

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Oct 15 / Roche and Genentech
Real-World Treatment Patterns Among Patients With Paroxysmal Nocturnal Hemoglobinuria Initiating Eculizumab and Ravulizumab: A US Claims Analysis
C5 inhibitors are standard of care for PNH treatment in the US, with intravenous eculizumab and ravulizumab having transformed clinical outcomes. To ensure optimal care for patients given the recent FDA approvals of newer complement inhibitors, this poster reports results from a US claims analysis on real-world treatment patterns in patients with PNH who initiated eculizumab or ravulizumab.
Haematology Atypical Haemolytic Uraemic Syndrome AMCP-NEXUS-2024

Sign up or login to unlock the full suite of MEDICALLY features
May 23 / Roche and Genentech
Crovalimab▼: Patient preferences and ongoing Phase III COMMUTE trials in acute haemolytic uraemic syndrome (aHUS)
Crovalimab▼ was shown to be well tolerated and efficacious in patients with PNH in the global, randomized Phase III COMMODORE 1 and 2 studies, and is currently being evaluated in the ongoing global, Phase III, single-arm COMMUTE-a and COMMUTE-p trials in aHUS. This poster reports results patient preference data from COMMODORE 1 and 2 patients who were treated with crovalimab▼ and eculizumab, as well as the study designs of COMMUTE-a and COMMUTE-p.
Nephrology Atypical hemolytic uremic syndrome ERA-2024

Sign up or login to unlock the full suite of MEDICALLY features
Nov 4 / Roche and Genentech
Phase III COMMODORE trials of crovalimab▼ in paroxysmal nocturnal hemoglobinuria (PNH): impact on kidney function
Crovalimab▼ was evaluated as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the Phase III COMMODORE 1, 2, and 3 studies. Crovalimab▼ is also being evaluated for atypical hemolytic uremic syndrome (aHUS), a complement-mediated disorder that directly affects the kidneys, in the COMMUTE-a and COMMUTE-p studies. This poster describes an analysis of kidney function in patients from the COMMODORE studies to further assess the feasibility of using crovalimab▼ to treat patients with aHUS.
Haematology Atypical Haemolytic Uraemic Syndrome ASN-Kidney-Week-2023

Sign up or login to unlock the full suite of MEDICALLY features
Jun 16 / Roche and Genentech
Rapid complement inhibition with the C5 inhibitor crovalimab▼: timing analysis using animal model and COMPOSER trial data
Both atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) are disorders characterized by dysregulated complement activation. In this analysis, time to complete complement inhibition after the first crovalimab▼ intravenous dose was evaluated using results from in vivo models of cynomolgus monkeys and from patients with paroxysmal nocturnal hemoglobinuria in the Phase I/II COMPOSER trial. The ongoing Phase III COMMUTE-a and COMMUTE-p trials evaluating crovalimab▼ in adult and pediatric patients with aHUS are also described.
Haematology Atypical Haemolytic Uraemic Syndrome ERA-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 3 / Roche and Genentech
Two Phase III trials evaluating crovalimab in patients with atypical hemolytic uremic syndrome (aHUS): COMMUTE-a and COMMUTE-p
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening complement-mediated disorder. Currently approved treatments include C5 inhibitors, which although effective, impose a significant treatment burden on patients, about 50% of whom are < 18 years old. Two Phase III studies, COMMUTE-a and COMMUTE-p will evaluate the efficacy and safety of crovalimab (anti-C5) in adult/adolescent and pediatric patients with aHUS, respectively.
Haematology Atypical Haemolytic Uraemic Syndrome ASN-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 24 / Roche and Genentech
Two Phase III trials evaluating crovalimab in patients with atypical hemolytic uremic syndrome (aHUS): COMMUTE-a and COMMUTE-p
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening complement-mediated disorder. Currently approved treatments include C5 inhibitors, which although effective, impose a significant treatment burden on patients, about 50% of whom are < 18 years old. Two Phase III studies, COMMUTE-a and COMMUTE-p will evaluate the efficacy and safety of crovalimab (anti-C5) in adult/adolescent and pediatric patients with aHUS, respectively.
Haematology Atypical Haemolytic Uraemic Syndrome ESPN-MEETING-2022

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.